Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Optimized Erythropoietin (EPO) Treatment (OETNA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by University of Iowa
Sponsor:
Collaborators:
Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
University of Iowa
ClinicalTrials.gov Identifier:
NCT02075970
First received: May 30, 2013
Last updated: June 12, 2014
Last verified: June 2014
  Purpose

Neonatal anemia is the most commonly encountered hematologic problem among all neonates cared for in the neonatal intensive care unit (NICU). This project seeks to better understand the pathophysiology and treatment of this challenging and important condition, especially as it affects premature, critically ill very low birth weight (VLBW) infants who require intensive laboratory blood monitoring leading to the need for multiple red blood cell (RBC) transfusions (RBCTX). In the research strategy proposed in Study 1, Aims 1, 2 and 3, recombinant human erythropoietin (Epoetin Alpha, PROCRIT, provided by Janssen Scientific Affairs) will first be administered to 1.0 to 1.5 kg VLBW infants; then comprehensive pharmacokinetics (PK) and pharmacodynamics (PD) data will be systematically gathered and analyzed to identify clinical and laboratory covariate parameters differentiating the infants based on their level of Epoetin Alpha responsiveness. Finally the Epoetin Alpha responsiveness predictors thus determined will be applied prospectively in the Aim 4 Study, a 2 x 2 design in which VLBW infants will be identified as good or poor Epoetin Alpha responders, based on the predictors, and then randomly assigned to receive Epoetin Alpha treatment or no treatment. This will test the central hypothesis: RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders. This project challenges the prevailing thinking that the efficacy of Epoetin Alpha dosing in stimulating erythropoiesis is insufficient to eliminate the need for RBC transfusions in VLBW infants. Based on extensive preclinical and clinical PK/PD studies by our PPG team, we contend that previous Erythropoietin treatment studies in VLBW infants were not able to realize the full potential of Erythropoietin to eliminate RBCTX (in contrast to the very successful use of Erythropoietin in adult renal failure patients) because previous VLBW studies were conducted 1) without Epoetin Alpha dosing individualized for the complexities of neonatal erythropoiesis and PK/PD of Epoetin Alpha and 2) without consistent criteria for RBC transfusion, Epoetin Alpha dosing, and patient enrollment. Net Epoetin Alpha responsiveness as reflected in Hb level depends on two components: Epoetin Alpha PD and RBC lifespan (Fig 15). By determining RBC lifespan, we will explain inter-subject variability of Epoetin Alpha responsiveness resulting from one of these components. The fetal lifespan data will be examined for its correlation with gestational age. If the correlation is statistically significant, gestational age will be included in the final selection of covariates for the population PK/PD model to be developed at the end of Infant Study 1. To fully understand the correlation of RBC lifespan with gestational age infants ranging from 22-42 weeks gestational age will be studied. The overall impact of Project 1 will be significant and potentially transformative: the development of a personalized, mechanism-driven approach built on sound principles will improve understanding of neonatal anemia and will be applicable to the care of premature, anemic infants.

RELEVANCE Project 1 results confirming our hypothesis that PK/PD optimized Epo treatment is effective in eliminating RBC transfusions administered to a select sub-group of NICU infants will provide fundamental knowledge about neonatal anemia that will reduce the burden of illness and disability caused by this condition. In addition, our results will stimulate researchers to extend our findings to other sub-groups with neonatal anemia, ie, smaller and sicker infants, and will stimulate novel treatments with similar, new biotechnology-produced protein drugs.


Condition Intervention Phase
Neonatal Anemia
Drug: Epoetin Alpha
Drug: Biotinylated Red Blood Cells
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Optimized EPO Treatment of Neonatal Anemia

Resource links provided by NLM:


Further study details as provided by University of Iowa:

Primary Outcome Measures:
  • Number of red blood cell transfusions [ Time Frame: From date of randomization through day of life 28 or death, whichever comes first ] [ Designated as safety issue: No ]
    The count of the number of packed red blood cell transfusions an infant receives during the entire course of their initial hospital stay.


Secondary Outcome Measures:
  • Survival of Fetal Red Blood Cells in number of days [ Time Frame: From date of transfusion of biotinylated red blood cells until biotinylated red blood cells are no longer detectable in leftover blood samples, or death, whichever comes first. An expected average of 80-120 days. Assessed up to 5 months. ] [ Designated as safety issue: No ]
    The count of the number of days that biotinylated red blood cells are identified in leftover blood samples. Counted from the day of transfusion until they are no longer able to be identified.


Other Outcome Measures:
  • Derivation of an individualized, optimal Epoetin Alpha dosing algorithm and prediction model for each subject [ Time Frame: From birth through discharge or death, whichever comes first. An average of 4 weeks to 6 months. Assessed up to 12 months. ] [ Designated as safety issue: No ]
    Using the covariates, red cell transfusions, blood loss due to labs, and growth, a model will be developed that will accurately predict individual Epoetin Alpha responsiveness to optimized Epoetin Alpha dosing.


Estimated Enrollment: 62
Study Start Date: June 2014
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Epoetin Alpha study 1

Epoetin Alpha Tthe number of separate doses (per kg) to be given over 4 weeks by day of age will not exceed 10. These will be administered as follows: day of life (DOL) 2 (1200 U), DOL 4 (600 U), DOL 5 (600 U), DOL 6 (600U), DOL 7 (600 U), DOL 9 (600 U), DOL 14 (600 U), DOL 15 (600 U), DOL 16 (1200 U), and DOL 28 (600 U). The greatest dose in any 1 wk period is 3600 U.

Infant study 1 Drug Intervention: all infants will be treated with Epoetin Alpha during the first four weeks of life to provide data for determining: 1) the PK/PD model determined optimized Epoetin Alpha dosing schedule; and 2) clinical and laboratory covariates predictive of which infants are good and poor Epoetin Alpha responder.

Drug: Epoetin Alpha

Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.

Infant study 2:

Dosing algorithm will be determined by results of Infant Study 1.

Other Name: Procrit
Placebo Comparator: Epoetin Alpha study 2

Epoetin Alpha dosing schedule will be determined based on the results of Infant Study 1.

Infant Study 2 is a randomized, masked study to test the hypothesis that optimized Epoetin Alpha treatment of VLBW infants predicted to be good responders will result in the elimination of RBCTx relative to poor responders.

Infant Study 2 in Years 4 and 5 will make use of the knowledge acquired in Infant Study 1 to test the central hypothesis that RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders.

Drug: Epoetin Alpha

Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.

Infant study 2:

Dosing algorithm will be determined by results of Infant Study 1.

Other Name: Procrit
Experimental: Biotinylated red blood cells
Individual fetal RBC lifespans will be determined by administering biotinylated red blood cells, both autologous and allogeneic, simultaneously. Left over red blood cells are examined to determine red cell survival.
Drug: Biotinylated Red Blood Cells
Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
Other Name: BioRBC

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   up to 2 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Post-menstrual age at birth less than 37 wk;
  2. birth weight of 1,001 to 1,500 g;
  3. postnatal age <48 h;
  4. respiratory distress requiring ventilation;
  5. signed consent by parent or guardian.

Exclusion Criteria:

  1. Anticipated survival <72 h;
  2. Hemolytic anemia due to alloimmune disease (including due to ABO), and other hemolytic disease processes;
  3. Major anomalies that are life-threatening during the neonatal and infant periods (central nervous system, cardiac, metabolic chromosomal including, but not limited to, trisomies, deletions, and trinucleotide repeats);
  4. Clinical seizures;
  5. Congenital thrombotic or hemorrhagic conditions including disseminated intravascular coagulation;
  6. Positive blood or spinal fluid bacterial or fungal culture, or other laboratory and/or clinical data indicative of sepsis, including TORCH infections, prior to 48 h of age;
  7. Hematocrit >50%;
  8. Platelet count >400,000 per µL in first 48 h of life;
  9. Hypertension with systolic blood pressure >100 mm Hg.
  10. Any condition, in the opinion of the investigators, that would compromise the well being of the subject or the study, or prevent the subject from meeting or performing study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02075970

Contacts
Contact: John A Widness, MD 319-356-8102 john-widness@uiowa.edu
Contact: Gretchen A Cress, BS 319-356-2151 gretchen-cress@uiowa.edu

Locations
United States, Iowa
University of Iowa Hospitals and Clinics Recruiting
Iowa City, Iowa, United States, 52242
Principal Investigator: John A Widness, MD         
Sub-Investigator: Gretchen A Cress, BS         
Sponsors and Collaborators
University of Iowa
Janssen Scientific Affairs, LLC
Investigators
Principal Investigator: John A Widness, MD University of Iowa
  More Information

No publications provided

Responsible Party: University of Iowa
ClinicalTrials.gov Identifier: NCT02075970     History of Changes
Other Study ID Numbers: 2013EPO, 3P01HL046925
Study First Received: May 30, 2013
Last Updated: June 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Iowa:
Neonatal
Anemia
Transfusion
Erythropoetin
Epoetin Alpha
Red Blood Cell
Survival
Pharmacodynamics
Model

Additional relevant MeSH terms:
Anemia
Anemia, Neonatal
Hematologic Diseases
Infant, Newborn, Diseases
Epoetin alfa
Hematinics
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014